Symposium Addresses Unique Needs of Young Adults with Rheumatic Diseases PDF Print E-mail
Wednesday, 05 October 2011 07:55

The Arthritis Foundation is sponsoring the 2nd Annual Arthritis in PrimeTime symposium on Saturday, October 22 at the Long Beach Renaissance Hotel in Long Beach. This premier educational and motivational event fosters active and fulfilling lives for young adults (ages 17-45 years old) affected by arthritis, fibromyalgia, lupus, scleroderma, ankylosing spondylitis and other chronic diseases. 



The event's theme is "Making My Work Work–"Work" being broadly defined as college, disability, life transitions, home-making or career. Led by top medical experts and advocates, informational sessions will educate hundreds of participants with chronic diseases about diverse lifestyle issues (including transition from college to the job market, workplace success, social relationships and health insurance issues), as well as research updates and medical treatments for pain management.  

"Most people do not know that arthritis is the #1 cause of work disability in the United States," said Arthritis in PrimeTime chair, Amye Leong, M.B.A. "Arthritis in PrimeTime is a positive, motivating event designed to help over 11 million young people affected with arthritis and other rheumatic diseases lead active, productive lives."  Ms. Leong, who was wheelchair-bound by rheumatoid arthritis, is today the international spokesperson for the United Nations Bone and Joint Decade.

Arthritis in PrimeTime is made possible through the Jane Wyman Trust and Pfizer, and is conducted in partnership with LupusLA, National Fibromyalgia Association, Scleroderma Foundation, Spondylitis Association of America, and Arthritis Introspective. 

The symposium begins at 9 a.m., and ends with an inspirational closing address by Matt Iseman, M.D., renowned comedian and host of Style Network's "Clean House."  Tickets are $25 each or $40 per couple. 

For more information or to register for this event, visit www.arthritisinprimetime.org or contact Jennifer Ziegler at the Arthritis Foundation at 323.954.5760 Ext. 243.

Source: PRNewswire


 
More articles :

» Promedior Announces Publication of New Research Demonstrating Pentraxin-2/SAP is a Potent Inhibitor of Pulmonary Fibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today the publication of collaborative research in the International Journal of Biochemistry and Cell Biology...

» HSCT Benefits In Early Diffuse Cutaneous Systemic Sclerosis

Initial results from an international, investigator-initiated, open label phase 3 trial, presented at EULAR 2012, indicate that haematopoietic stem cell transplantation (HSCT) results in better long-term survival than conventional treatment for...

» Crowdsourcing A Cure For Scleroderma

is widely known for medical innovation — from the research laboratory to the patient’s bedside — but in partnership with dedicated donors, the institution is also innovating the way it raises money to accelerate groundbreaking research.With...

» Scientists and Clinicians Address Diagnosis and Treatment for Autoimmune and Autoinflammatory Diseases

Autoimmune and autoinflammatory diseases are a major health issue. The National Institutes of Health reports that up to 23.5 million Americans are afflicted. The American Autoimmune Related Diseases Association reports the number is closer to 50...

» Cytokines in Systemic Sclerosis: Focus on IL-17

Julie Baraut, Dominique Farge, Elena Ivan-Grigore, Franck Verrecchia, and Laurence MichelSystemic sclerosis (SSc) is an autoimmune disease characterized by progressive sclerosis of the skin and internal organ dysfunction. Cytokine production and...

» Beware of Skin Signs of Illness and Disease

While moisturizers and make-up, facial peels and Botox can make our skin look beautiful and young, sometimes the external skin discolorations, blemishes, blotches or other unsightly marks we seek to remove are actually signs of an underlying...